Malvern Instruments and Netzsch Grinding & Dispersing Sign Agreement to Cooperate - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Malvern Instruments and Netzsch Grinding & Dispersing Sign Agreement to Cooperate

UK-based Malvern Instruments and Germany-based Netzsch Grinding & Dispersing have entered into a cooperative marketing agreement for a broad range of market sectors, including pharmaceuticals, announced Netzsch in an April 23 press release.

The global agreement, initially in place for three years, will harness the strength of each company’s brands and unique expertise in materials processing and materials characterization. Under the terms of the agreement, Netzsch will standardize on Malvern’s particle-sizing and characterization equipment, primarily the Mastersizer 3000 laser diffraction particle size analyzer. Customers and prospective customers of each company will gain access both to the extensive milling knowledge of the Netzsch teams and to the particle sizing know-how of Malvern Instruments.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here